Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results [Yahoo! Finance]
Soleno Therapeutics, Inc. (SLNO)
Last soleno therapeutics, inc. earnings: 5/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.soleno.life/investor-overview
Company Research
Source: Yahoo! Finance
novel therapeutics for the treatment of rare diseases, today announced select preliminary financial and operating results for the fourth quarter and full-year 2025: Preliminary unaudited full-year 2025 net revenue related to U.S. sales of VYKAT™ XR since second quarter launch expected to be in a range of $189 million to $191 million. Preliminary unaudited fourth quarter 2025 net revenue expected to be in a range of $90 million to $92 million. 1,250 total new patient start forms (207 in the fourth quarter) from launch through December 31, 2025, or approximately 12.5% of the total U.S. VYKAT XR addressable market. Discontinuation rate of VYKAT XR related to adverse events was approximately 12% as of the end of the fourth quarter. 630 unique prescribers, including 136 new prescribers in the fourth quarter. Over 185 million lives covered, or approximately 60% of total lives. Company has responded to Day 120 questions received from the European Medicines Agency. Company has
Show less
Read more
Impact Snapshot
Event Time:
SLNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLNO alerts
High impacting Soleno Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SLNO
News
- SLNO INVESTOR ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Fraud InvestigationGlobeNewswire
- Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% -- Hagens BermanGlobeNewswire
- Soleno Therapeutics: Why I'm Staying On The Sidelines [Seeking Alpha]Seeking Alpha
- Soleno Therapeutics (NASDAQ:SLNO) was given a new $107.00 price target on by analysts at Robert W. Baird.MarketBeat
- SLNO Investors: Contact Kirby McInerney LLP About Investigation into Soleno Therapeutics, Inc.Business Wire
SLNO
Earnings
- 11/4/25 - Beat
SLNO
Sec Filings
- 1/12/26 - Form 8-K
- 12/17/25 - Form 4
- 12/17/25 - Form 4
- SLNO's page on the SEC website